Spasticity Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Jazz Pharmaceuticals, Revance Therapeutics, Ipsen

The Key Spasticity Companies in the market include - Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others.

The Spasticity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spasticity pipeline products will significantly revolutionize the Spasticity market dynamics.

DelveInsight's "Spasticity Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spasticity market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Spasticity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spasticity Market Insights [https://www.delveinsight.com/sample-request/spasticity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Spasticity Market Report:

*
The Spasticity market size was valued approximately USD 904 million in 2021 is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In December 2024, Health Canada approved XEOMIN Registered (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity in adults. This marks a key advancement in Canadian healthcare, expanding the therapeutic reach of XEOMIN and allowing clinicians to treat both upper and lower limb spasticity in a single patient, using up to a total of 600 units. This label extension reinforces XEOMIN's essential role in neurological rehabilitation-from enhancing mobility to alleviating pain. Each year, over 109,000 Canadians suffer strokes, and many survivors develop spasticity within a year. This latest approval is XEOMIN's sixth indication in Canada, alongside uses such as cervical dystonia and chronic sialorrhea.

*
In October 2024, Saol Therapeutics, a privately-owned clinical-stage pharmaceutical firm, has reported positive topline results from its SL-1002 RAISE Limb Spasticity Trial (NCT05311215). These findings were recently shared during the Spasticity X Symposium held in Houston, Texas.

*
In January 2024, Ipsen (Euronext: IPN; ADR: IPSEY) recently revealed top-line results from its real-world AboLiSh study (NCT04050527), presented at the 7th International TOXINS Conference in Berlin, Germany. The study assessed the use and effectiveness of Dysport Registered (abobotulinumtoxinA) in individuals with lower-limb spasticity, highlighting that injection guidance techniques notably enhance patient outcomes and goal achievement.

*
Spasticity is one of the most common symptoms of multiple sclerosis (MS) and is defined as muscle stiffness that is frequently generalized and that causes more or less continuous rigidity

*
There were approximately 2,328,000 prevalent cases of Spasticity in the United States in 2021

*
According to the analysis, DelveInsight estimated approximately 415,000 prevalent cases of Spasticity in Germany in 2021

*
Key Spasticity Companies: Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others

*
Key Spasticity Therapies: Nabiximols, DAXI, IPN10200, and others

*
The Spasticity epidemiology based on gender analyzed that Males are more at risk of developing Spasticity in comparison to the females

Spasticity Overview

Spasticity is defined as "sensorimotor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex" or from an upper motor neuron lesion (UMN),presenting as an intermittent or sustained involuntary activations of muscles. The region and the extent of impairment depend on the area of the brain or spinal cord that has been damaged. It can occur in the upper and/or lower limbs

Get a Free sample for the Spasticity Market Report:

https://www.delveinsight.com/report-store/spasticity-market [https://www.delveinsight.com/report-store/spasticity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Spasticity Market

The dynamics of the Spasticity market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032.

"The emerging therapies for the treatment of Spasticity include Nabiximols, DAXI and others. Approval of these therapies will provide new and different treatment options to the patients and will hence drive the market."

Spasticity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Spasticity Epidemiology Segmentation:

The Spasticity market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Spasticity

*
Prevalent Cases of Spasticity by severity

*
Gender-specific Prevalence of Spasticity

*
Diagnosed Cases of Episodic and Chronic Spasticity

Download the report to understand which factors are driving Spasticity epidemiology trends @ Spasticity Epidemiological Insights [https://www.delveinsight.com/sample-request/spasticity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Spasticity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spasticity market or expected to get launched during the study period. The analysis covers Spasticity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spasticity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Spasticity Therapies and Key Companies

*
Nabiximols: Jazz Pharmaceuticals

*
DAXI: Revance Therapeutics

*
IPN10200: Ipsen

To know more about Spasticity treatment, visit @ Spasticity Medications [https://www.delveinsight.com/sample-request/spasticity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Spasticity Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Spasticity Companies: Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others

*
Key Spasticity Therapies: Nabiximols, DAXI, IPN10200, and others

*
Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies

*
Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Spasticity Unmet Needs, KOL's views, Analyst's views, Spasticity Market Access and Reimbursement

Discover more about therapies set to grab major Spasticity market share @ Spasticity Treatment Landscape [https://www.delveinsight.com/sample-request/spasticity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Spasticity Market Report Introduction

2. Executive Summary for Spasticity

3. SWOT analysis of Spasticity

4. Spasticity Patient Share (%) Overview at a Glance

5. Spasticity Market Overview at a Glance

6. Spasticity Disease Background and Overview

7. Spasticity Epidemiology and Patient Population

8. Country-Specific Patient Population of Spasticity

9. Spasticity Current Treatment and Medical Practices

10. Spasticity Unmet Needs

11. Spasticity Emerging Therapies

12. Spasticity Market Outlook

13. Country-Wise Spasticity Market Analysis (2019-2032)

14. Spasticity Market Access and Reimbursement of Therapies

15. Spasticity Market Drivers

16. Spasticity Market Barriers

17. Spasticity Appendix

18. Spasticity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spasticity-market-predicted-to-see-upsurge-through-2032-highlights-delveinsight-jazz-pharmaceuticals-revance-therapeutics-ipsen]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.